Bayer's Triple Play: A Landmark Ruling, a $300 Million Acquisition, and a High-Stakes Pipeline Push
28.06.2026 - 20:12:11 | boerse-global.de
The June 25 Supreme Court decision barring individual states from mandating separate cancer warnings on glyphosate products delivered a powerful jolt to Bayer shares — the stock surged roughly 23% on the week to close at €46.61. Yet the court’s blessing is only one piece of a much larger puzzle. The German life sciences group is simultaneously pressing forward on multiple fronts: a freshly inked artificial intelligence partnership, a $300 million bet on an experimental eye implant, and a late-stage stroke drug that could reshape its pharma pipeline.
AI and Ophthalmology: Two New Arrows in the Pharma Quiver
Bayer has struck a deal with US biotech Iambic Therapeutics to apply AI-driven discovery platforms — Enchant and NeuralPLexer — to hunt for small molecules against tough-to-drug targets in oncology and other therapeutic areas. Iambic will receive an upfront payment plus milestone and royalty fees; Bayer declined to disclose specific amounts.
More immediately tangible is the completed acquisition of Perfuse Therapeutics, sealed in June for $300 million upfront. The total consideration could reach $2.45 billion, contingent on development and regulatory milestones. The crown jewel is PER-001, a phase II intravitreal implant targeting glaucoma and diabetic retinopathy — conditions that affect roughly 80 million and 146 million people worldwide, respectively. Bayer positions the asset as a potential first-in-class therapy with no direct alternative, complementing its existing ophthalmology franchise anchored by Eylea.
A New CFO Inherits a Debt-Laden Balance Sheet
These growth investments are unfolding against a backdrop of strained finances. Dr. Judith Hartmann took the reins as chief financial officer on June 1, succeeding the retiring Wolfgang Nickl. Her inbox is hardly welcoming: Bayer expects litigation-related cash outflows of roughly €5 billion this year alone, dragging free cash flow into negative territory of €1.5 billion to €2.5 billion. Net financial debt could climb to between €32 billion and €33 billion by year-end, up from just under €30 billion at the close of 2025.
Should investors sell immediately? Or is it worth buying Bayer?
Hartmann will present her first updated outlook when Bayer releases second-quarter results in August — after a quiet period running from July 15 to August 4. Investors will scrutinize whether the Supreme Court victory translates into meaningful debt reduction or merely masks continued underlying pressure.
Asundexian: The Pipeline’s Make-or-Break Catalyst
While the legal calendar dominates headlines, the fate of Bayer’s stock may ultimately hinge on Asundexian. The novel stroke prevention candidate reduced ischemic strokes by 26% versus placebo in the pivotal phase III OCEANIC-STROKE trial, without elevating bleeding risk. Regulatory momentum is building: the EMA has initiated the central review process, the FDA accepted the application in May 2026 and granted priority review, and Chinese regulators have also awarded priority review status. Clearances in all three markets would hand Bayer a first-mover advantage over Bristol Myers Squibb and Johnson & Johnson’s rival drug Milvexian.
Yet the clock is ticking. Patent expirations are eroding the legacy portfolio: Xarelto slumped 31.6% in constant-currency terms in 2025, and Eylea fell 3.7% under pricing pressure in Canada, the UK, Japan, and generic competition. Asundexian must fill that gap — and any regulatory setback would undermine the bull case.
The July 9 Settlement Hearing: A Legal Pivot Point
Bayer’s $7.25 billion glyphosate settlement, provisionally approved in February, faces its final court hearing on July 9 in Missouri. A smooth confirmation would largely close the most expensive litigation chapter in the company’s history. But some plaintiff lawyers continue to criticize the deal, and a collapse would reignite uncertainty — potentially puncturing the rally.
The technical picture adds a cautionary note. With a 14-day RSI of 80.6, the stock is overbought and trading roughly 23% above its 50-day moving average. The near-term resistance lies at the 52-week high of €49.93. If the settlement hearing goes smoothly and Asundexian continues to advance without hitches, that level could come into play. If not, the stretched valuation leaves little margin for error.
Bayer at a turning point? This analysis reveals what investors need to know now.
Bayer’s broader guidance for 2026 — group revenue of €44 billion to €46 billion and EBITDA before special items of €9.1 billion to €9.6 billion — is based on year-end 2025 exchange rates, highlighting the currency headwinds that also cloud the outlook. The crop science division, though stable with 2025 revenue of €21.6 billion, is hardly a growth engine.
Alongside all this, some shareholders are pushing for a spin-off of the consumer health unit — a debate that is likely to surface again at the next annual general meeting. For now, the coming weeks will test whether Bayer can transform legal relief into operational renewal.
Ad
Bayer Stock: New Analysis - 28 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
